Johan Kördel is interviewed about Sound Bioventures and its Investment Strategy by BioStock

Johan Kördel - Sound Bioventures

To be able to contribute to the development of new drugs is very exciting! I am passionate about helping people to a better life – says Johan Kördel

Sound Bioventures strategy is to invest in private clinical stage therapeutics companies. In the interview Johan expands on the opportunity to create private spin-outs from public companies, that in some cases trade for less than their cash, and raise money from venture funds to allow clinical programs to advance. This opportunity has arisen with the suppressed public valuations the biotech sector has seen the last year. Read the full interview below.

About BioStock

BioStock is Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector. BioStock’s content is aimed at investors and representatives of companies and organizations in biotechnology, medical technology, diagnostics and drug development. BioStock’s daily news updates are followed by a majority of decision-makers at management level in Nordic life science.

Subscribe

* indicates required

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...

Subscribe

* indicates required